Juventas reported interim 4-month data from the double-blind, U.S. Phase II STOP-HF trial in 93 patients with symptomatic ischemic cardiomyopathy showing that a single injection of 30 mg JVS-100 non-significantly improved left ventricular end systolic...

Data from a double-blind, international, Phase III (RFA-DK-03-004) trial in 272 men showed that alfuzosin missed the primary endpoint of percentage of patients who achieved >=4-point decrease on the NIH-CPSI vs. placebo (49% in both...